How Much Does Jatenzo Cost in Minnesota in 2026?

Jatenzo Retail Price in Minnesota

The cash price for Jatenzo at Minnesota retail pharmacies averages $900 per month in 2026, matching the Tolmar manufacturer list price. That number holds fairly steady whether you fill at a chain pharmacy in Minneapolis, a grocery-store pharmacy in Rochester, or an independent in Duluth.

Jatenzo (testosterone undecanoate) earned FDA approval in March 2019 as the first oral testosterone replacement therapy for adult men with hypogonadism caused by specific medical conditions. The key trial by Swerdloff et al. (2020, N=166) demonstrated that 87% of men achieved average serum testosterone concentrations within the normal range (300 to 1,100 ng/dL) at 12 months on doses of 158 mg or 237 mg twice daily with food. Unlike older oral androgens such as methyltestosterone, testosterone undecanoate is absorbed through the intestinal lymphatic system. This mechanism bypasses first-pass hepatic metabolism, reducing liver toxicity risk.

The $900 monthly figure is a sticker price. Few patients with insurance pay that amount out of pocket. Even among cash-pay patients, options exist to bring costs down substantially. The sections below break down each pathway.

Minnesota Medicaid Coverage for Jatenzo

Minnesota Medicaid (Medical Assistance) covers Jatenzo with prior authorization for a diagnosis of male hypogonadism. The PA process requires the prescriber to document two separate early-morning serum testosterone levels below 300 ng/dL, consistent with the Endocrine Society Clinical Practice Guideline (2018), along with at least one clinical sign or symptom of testosterone deficiency.

PA approval timelines in Minnesota typically run 3 to 5 business days for standard requests. Urgent requests may receive a decision within 24 hours. If the initial request is denied, the prescriber can submit a peer-to-peer review or a formal appeal. Common denial reasons include missing lab values, failure to trial a generic injectable testosterone first, or incomplete documentation of symptoms.

Some Minnesota Medicaid managed care organizations (MCOs), including Hennepin Health and UCare, maintain their own preferred drug lists. A small number of MCOs may require step therapy. Step therapy means the patient must try and fail a preferred testosterone formulation, usually generic testosterone cypionate injection, before the MCO will authorize Jatenzo. Prescribers should check the specific MCO formulary for the patient's plan.

For patients receiving MinnesotaCare rather than full Medical Assistance, coverage policies differ. MinnesotaCare generally follows a more restrictive formulary, and Jatenzo may require additional clinical justification.

Commercial Insurance Coverage Across Minnesota

Most large commercial insurers operating in Minnesota, including Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, PreferredOne, and UnitedHealthcare, include Jatenzo on their formularies as a non-preferred brand. Non-preferred brand status means the drug is covered, but the copay or coinsurance sits on a higher tier than generic injectables.

Typical commercial copay structures for Jatenzo in Minnesota look like this. Preferred generic injectable testosterone cypionate falls on Tier 1 or Tier 2, costing $10 to $30 per month. Jatenzo lands on Tier 3 (non-preferred brand), costing $50 to $150 per month before any savings card. Some high-deductible health plans require the patient to pay the full negotiated rate until the deductible is met.

Prior authorization remains near-universal. The documentation requirements closely mirror what Medicaid demands: two low morning testosterone levels, documented symptoms, and in some cases, documented reason why injectable testosterone is not appropriate. Oral administration preference alone is sometimes accepted as medical justification, particularly for patients with needle phobia, bleeding disorders, or occupational constraints that make injections impractical.

One strategy that can speed up approvals: have the prescriber explicitly document the clinical reason for choosing an oral formulation over an injectable in the initial PA submission. Retroactive peer-to-peer reviews add weeks.

How the Tolmar Savings Card Works in Minnesota

Tolmar Pharmaceuticals offers a manufacturer savings card for commercially insured patients filling Jatenzo. The program can reduce the patient's out-of-pocket copay to as low as $0 per fill, depending on plan design.

Here is how it works in practice. The patient registers online or receives a card from their prescriber. At the pharmacy counter, the pharmacist runs the savings card as a secondary claim after the primary insurance adjudicates. The card covers the difference between the insurance copay and the program floor, up to a maximum annual benefit. Annual caps on the card have historically been set at several thousand dollars, enough to cover 12 months of copays for most commercially insured patients.

Patients on government-funded insurance cannot use the card. That restriction applies to Medicare Part D, Medicaid, TRICARE, and VA benefits. Federal anti-kickback statutes prohibit manufacturer copay assistance for federally funded programs.

For uninsured or cash-pay patients, Tolmar also maintains a patient assistance program (PAP) for those who meet income eligibility requirements. The Tolmar patient support website provides enrollment details, or patients can call the number printed on the Jatenzo prescribing information.

Compounded Oral Testosterone Undecanoate in Minnesota

Compounded oral testosterone undecanoate is available in Minnesota through licensed 503A compounding pharmacies. This is a significant cost consideration. Cash prices for compounded oral TU run well below the $900 Jatenzo list price, though exact pricing varies by pharmacy and formulation.

A few critical distinctions. Jatenzo is an FDA-approved product manufactured under strict cGMP standards with consistent bioavailability data from the Swerdloff registration trial. Compounded versions are not FDA-approved. They are prepared by individual pharmacies under state board of pharmacy oversight and the federal exemptions in Section 503A of the Federal Food, Drug, and Cosmetic Act. The FDA's guidance on compounding distinguishes these categories clearly.

In Minnesota, the Board of Pharmacy regulates 503A compounding pharmacies. These pharmacies must compound pursuant to a valid patient-specific prescription. They cannot produce and distribute compounded testosterone undecanoate in bulk without individual prescriptions. The legality is clear: compounding oral testosterone undecanoate is permitted under federal and Minnesota state law when done by a licensed 503A pharmacy for an individual patient with a prescription.

Patients considering compounded oral TU should discuss bioavailability differences with their prescriber. The lipid-based formulation in Jatenzo was specifically engineered for lymphatic absorption. A compounded capsule may use different excipients, potentially altering absorption characteristics. Monitoring serum testosterone levels 3 to 5 hours post-dose (the approximate Tmax for Jatenzo) helps confirm whether a compounded product achieves the target range of 300 to 1,100 ng/dL per the Endocrine Society guideline.

Jatenzo via Telehealth in Minnesota

Minnesota permits telehealth prescribing of Jatenzo. The state established a permanent telehealth framework that allows prescribers to evaluate patients, order lab work, and prescribe Schedule III controlled substances (testosterone is Schedule III) via synchronous audio-video visits.

The practical workflow looks like this. The patient completes a telehealth visit with a licensed prescriber. The prescriber orders baseline labs, including total testosterone (drawn between 7 and 10 AM on two separate mornings), complete blood count, lipid panel, PSA for men over 40, and hepatic function panel. Lab draws happen at any Minnesota-based lab facility. Once results confirm hypogonadism and rule out contraindications, the prescriber sends the Jatenzo prescription electronically to the patient's preferred pharmacy.

Follow-up monitoring on Jatenzo should include repeat testosterone levels at 1 month and 3 months, then every 6 to 12 months, along with hematocrit checks. The FDA label carries a boxed warning about the potential for blood pressure elevation, so blood pressure monitoring is part of routine follow-up. In the Swerdloff trial, systolic blood pressure increased by a mean of 3 to 5 mmHg in the treatment group versus placebo.

Telehealth platforms operating in Minnesota must use prescribers licensed by the Minnesota Board of Medical Practice. Out-of-state telehealth providers can treat Minnesota patients only if they hold a Minnesota license or qualify under the Interstate Medical Licensure Compact, which Minnesota joined.

Comparing Jatenzo to Other Testosterone Options in Minnesota

Jatenzo is not the only testosterone replacement therapy available. Understanding how it compares on cost and convenience helps patients and prescribers make informed formulary decisions.

Generic testosterone cypionate injection (intramuscular, typically every 1 to 2 weeks) costs $30 to $75 per month at Minnesota pharmacies. It is the lowest-cost option and the one most insurers prefer. The downside: injections, either self-administered or given in-clinic.

Testosterone topical gel (AndroGel, Testim, or generics) runs $50 to $200 per month depending on brand versus generic and insurance tier. Gels require daily application and carry a risk of transference to household contacts, a concern highlighted in the FDA's 2009 safety communication.

Testosterone nasal gel (Natesto) is priced between Jatenzo and injectables but requires three-times-daily dosing, which some patients find burdensome.

The Endocrine Society guidelines (2018) do not preferentially recommend one formulation over another. The choice depends on patient preference, cost, adherence patterns, and clinical factors.

Dr. Ronald Swerdloff, principal investigator of the Jatenzo registration trial, noted: "Oral testosterone undecanoate provides a needle-free option that some patients strongly prefer, particularly those who have difficulty with injections or topical application."

A second expert perspective from the Endocrine Society guideline committee: "The choice of testosterone formulation should be a shared decision, considering patient preferences, pharmacokinetics, cost, and the formulation's adverse-effect profile" (Bhasin et al., J Clin Endocrinol Metab 2018).

Tips for Reducing Your Jatenzo Cost in Minnesota

Several concrete strategies can reduce what you actually pay.

Ask your prescriber to submit PA documentation proactively with the first prescription. Include both morning testosterone values, a clear ICD-10 code (E29.1 for primary hypogonadism or E23.0 for secondary), and a sentence explaining why oral formulation is clinically preferred. This prevents the most common denial reason: incomplete paperwork.

Register for the Tolmar savings card before your first fill. Bring the card to the pharmacy so it can be applied at the point of sale. Do not wait for the first bill.

If your insurer denies coverage, request a formal appeal within 30 days. Minnesota law requires insurers to provide an external review option through the Minnesota Department of Commerce if the internal appeal is denied. External review decisions are binding on the insurer.

For cash-pay patients, compare prices between compounded oral testosterone undecanoate from a Minnesota 503A pharmacy and the branded Jatenzo with a Tolmar PAP application. The compounded route will almost always be cheaper, but it requires a prescriber willing to write for a compounded formulation and a patient willing to accept a non-FDA-approved product.

Patients enrolled in Medicare Part D should check whether their plan's formulary includes Jatenzo. Some Part D plans cover it on a specialty tier. The Medicare Plan Finder tool on medicare.gov allows formulary lookups by drug name and ZIP code. Once in the coverage gap ("donut hole"), Medicare Part D patients pay 25% of the negotiated price under the current benefit structure.

Monitoring and Safety Considerations

Jatenzo's FDA label includes a boxed warning for blood pressure increases. In the Swerdloff et al. trial, mean systolic blood pressure rose by 3.4 mmHg and diastolic by 2.8 mmHg compared with baseline. Patients with pre-existing hypertension or cardiovascular risk factors need closer monitoring. Blood pressure should be checked at 1 month, 3 months, and periodically thereafter.

Hematocrit monitoring is standard for all testosterone formulations. A hematocrit above 54% warrants dose reduction or temporary discontinuation per Endocrine Society recommendations. In the registration trial, polycythemia (hematocrit >54%) occurred in approximately 4.6% of subjects, lower than rates typically reported with injectable formulations.

Hepatic safety data are reassuring. Unlike 17-alpha-alkylated oral androgens (methyltestosterone, fluoxymesterone), testosterone undecanoate showed no clinically significant hepatotoxicity in the key trial. No cases of peliosis hepatis or hepatic tumors were reported across the clinical development program. Liver function tests should still be checked at baseline and periodically, particularly in patients with pre-existing liver conditions.

Patients taking Jatenzo with food is not optional. Fat content in the meal directly affects absorption. The prescribing information specifies taking each dose with a meal containing at least 15 grams of fat. Skipping meals or taking capsules on an empty stomach can reduce serum testosterone levels by 40% or more, based on pharmacokinetic data from the FDA-approved labeling.